These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 32092588)

  • 1. Synthesis, biochemical, pharmacological characterization and in silico profile modelling of highly potent opioid orvinol and thevinol derivatives.
    Szűcs E; Marton J; Szabó Z; Hosztafi S; Kékesi G; Tuboly G; Bánki L; Horváth G; Szabó PT; Tömböly C; Varga ZK; Benyhe S; Ötvös F
    Eur J Med Chem; 2020 Apr; 191():112145. PubMed ID: 32092588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. C(21)-fluorinated thevinol scaffold for opioid ligands. 21,21,21-Trifluoro-6-O-nororvinols: Design, synthesis and analgesic activity.
    Sandulenko IV; Belozertseva IV; Zvartau EE; Zelentsova MV; Ambartsumyan AA; Smol'yakov AF; Moiseev SK
    Eur J Med Chem; 2023 Apr; 252():115296. PubMed ID: 36966650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthesis and biological evaluation of 14-alkoxymorphinans. 21. Novel 4-alkoxy and 14-phenylpropoxy derivatives of the mu opioid receptor antagonist cyprodime.
    Spetea M; Schüllner F; Moisa RC; Berzetei-Gurske IP; Schraml B; Dörfler C; Aceto MD; Harris LS; Coop A; Schmidhammer H
    J Med Chem; 2004 Jun; 47(12):3242-7. PubMed ID: 15163203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring pharmacological activities and signaling of morphinans substituted in position 6 as potent agonists interacting with the μ opioid receptor.
    Ben Haddou T; Malfacini D; Calo G; Aceto MD; Harris LS; Traynor JR; Coop A; Schmidhammer H; Spetea M
    Mol Pain; 2014 Jul; 10():48. PubMed ID: 25059282
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(indole-7-carboxamido)morphinan (NAN) as a Novel Opioid Receptor Modulator for Opioid Use Disorder Treatment.
    Obeng S; Jali A; Zheng Y; Wang H; Schwienteck KL; Chen C; Stevens DL; Akbarali HI; Dewey WL; Banks ML; Liu-Chen LY; Selley DE; Zhang Y
    ACS Chem Neurosci; 2019 May; 10(5):2518-2532. PubMed ID: 30758946
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and characterization of thiazolo- and thiazinomorphinans and their intermediate products as novel opioid-active derivatives.
    Sipos A; Follia V; Berényi S; Antus S; Schmidhammer H; Spetea M
    Arch Pharm (Weinheim); 2012 Nov; 345(11):852-8. PubMed ID: 22886624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, Pharmacology, and Molecular Docking Studies on 6-Desoxo-N-methylmorphinans as Potent μ-Opioid Receptor Agonists.
    Dumitrascuta M; Ben Haddou T; Guerrieri E; Noha SM; Schläfer L; Schmidhammer H; Spetea M
    J Med Chem; 2017 Nov; 60(22):9407-9412. PubMed ID: 29053268
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Docking, Molecular Dynamics, and Structure-Activity Relationship Explorations of 14-Oxygenated N-Methylmorphinan-6-ones as Potent μ-Opioid Receptor Agonists.
    Noha SM; Schmidhammer H; Spetea M
    ACS Chem Neurosci; 2017 Jun; 8(6):1327-1337. PubMed ID: 28125215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DAMGO and 6beta-glycine substituted 14-O-methyloxymorphone but not morphine show peripheral, preemptive antinociception after systemic administration in a mouse visceral pain model and high intrinsic efficacy in the isolated rat vas deferens.
    Al-Khrasani M; Spetea M; Friedmann T; Riba P; Király K; Schmidhammer H; Furst S
    Brain Res Bull; 2007 Oct; 74(5):369-75. PubMed ID: 17845912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel approach to demonstrate high efficacy of mu opioids in the rat vas deferens: a simple model of predictive value.
    Riba P; Friedmann T; Király KP; Al-Khrasani M; Sobor M; Asim MF; Spetea M; Schmidhammer H; Furst S
    Brain Res Bull; 2010 Jan; 81(1):178-84. PubMed ID: 19800397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N-Phenethyl Substitution in 14-Methoxy-N-methylmorphinan-6-ones Turns Selective µ Opioid Receptor Ligands into Dual µ/δ Opioid Receptor Agonists.
    Dumitrascuta M; Bermudez M; Ben Haddou T; Guerrieri E; Schläfer L; Ritsch A; Hosztafi S; Lantero A; Kreutz C; Massotte D; Schmidhammer H; Wolber G; Spetea M
    Sci Rep; 2020 Mar; 10(1):5653. PubMed ID: 32221355
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Pharmacological Heterogeneity of Nepenthone Analogs in Conferring Highly Selective and Potent κ-Opioid Agonistic Activities.
    Li W; Long JD; Qian YY; Long Y; Xu XJ; Wang YJ; Shen Q; Wang ZN; Yang XC; Xiao L; Sun HP; Xu YL; Chen YY; Xie Q; Wang YH; Shao LM; Liu JG; Qiu ZB; Fu W
    ACS Chem Neurosci; 2017 Apr; 8(4):766-776. PubMed ID: 28033462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, Synthesis, and Biological Evaluation of the Third Generation 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-[(4'-pyridyl)carboxamido]morphinan (NAP) Derivatives as μ/κ Opioid Receptor Dual Selective Ligands.
    Zheng Y; Obeng S; Wang H; Jali AM; Peddibhotla B; Williams DA; Zou C; Stevens DL; Dewey WL; Akbarali HI; Selley DE; Zhang Y
    J Med Chem; 2019 Jan; 62(2):561-574. PubMed ID: 30608693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3'-carboxamido)morphinan analogues as opioid receptor ligands.
    Yuan Y; Zaidi SA; Stevens DL; Scoggins KL; Mosier PD; Kellogg GE; Dewey WL; Selley DE; Zhang Y
    Bioorg Med Chem; 2015 Apr; 23(8):1701-15. PubMed ID: 25783191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and opioid receptor affinity of morphinan and benzomorphan derivatives: mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine dependence.
    Neumeyer JL; Bidlack JM; Zong R; Bakthavachalam V; Gao P; Cohen DJ; Negus SS; Mello NK
    J Med Chem; 2000 Jan; 43(1):114-22. PubMed ID: 10633042
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
    Mathews JL; Peng X; Xiong W; Zhang A; Negus SS; Neumeyer JL; Bidlack JM
    J Pharmacol Exp Ther; 2005 Nov; 315(2):821-7. PubMed ID: 16076937
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological properties and biochemical mechanisms of μ-opioid receptor ligands might be due to different binding poses: MD studies.
    Ronsisvalle S; Panarello F; Spadaro A; Franchini S; Pappalardo M; Guccione S; Basile L
    Future Med Chem; 2020 Nov; 12(22):2001-2018. PubMed ID: 32972243
    [No Abstract]   [Full Text] [Related]  

  • 18. Mixed κ/μ partial opioid agonists as potential treatments for cocaine dependence.
    Bidlack JM
    Adv Pharmacol; 2014; 69():387-418. PubMed ID: 24484983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 17-Cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6β-(4'-pyridylcarboxamido)morphinan (NAP) Modulating the Mu Opioid Receptor in a Biased Fashion.
    Zhang Y; Williams DA; Zaidi SA; Yuan Y; Braithwaite A; Bilsky EJ; Dewey WL; Akbarali HI; Streicher JM; Selley DE
    ACS Chem Neurosci; 2016 Mar; 7(3):297-304. PubMed ID: 26716358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and biological evaluation of 14-alkoxymorphinans. 22.(1) Influence of the 14-alkoxy group and the substitution in position 5 in 14-alkoxymorphinan-6-ones on in vitro and in vivo activities.
    Lattanzi R; Spetea M; Schüllner F; Rief SB; Krassnig R; Negri L; Schmidhammer H
    J Med Chem; 2005 May; 48(9):3372-8. PubMed ID: 15857143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.